1. Home
  2. MSI vs ARGX Comparison

MSI vs ARGX Comparison

Compare MSI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Motorola Solutions Inc.

MSI

Motorola Solutions Inc.

HOLD

Current Price

$372.29

Market Cap

61.3B

Sector

Technology

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$893.01

Market Cap

51.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSI
ARGX
Founded
1928
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.3B
51.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
MSI
ARGX
Price
$372.29
$893.01
Analyst Decision
Buy
Strong Buy
Analyst Count
6
17
Target Price
$502.50
$925.94
AVG Volume (30 Days)
1.6M
348.9K
Earning Date
10-30-2025
10-30-2025
Dividend Yield
1.31%
N/A
EPS Growth
36.31
N/A
EPS
12.46
23.27
Revenue
$11,313,000,000.00
$3,683,281,000.00
Revenue This Year
$8.75
$91.22
Revenue Next Year
$8.25
$36.36
P/E Ratio
$29.75
$35.81
Revenue Growth
6.18
92.98
52 Week Low
$365.40
$510.06
52 Week High
$492.22
$934.62

Technical Indicators

Market Signals
Indicator
MSI
ARGX
Relative Strength Index (RSI) 31.01 51.14
Support Level $369.05 $886.50
Resistance Level $374.94 $917.71
Average True Range (ATR) 6.24 17.58
MACD 2.51 -6.77
Stochastic Oscillator 37.89 7.87

Price Performance

Historical Comparison
MSI
ARGX

About MSI Motorola Solutions Inc.

Motorola Solutions is a leading provider of communications and analytics, primarily serving public safety departments as well as schools, hospitals, and businesses. The bulk of the firm's revenue comes from sales of land mobile radios and radio network infrastructure, but the firm also sells surveillance equipment, dispatch software, and other networking capabilities. Most of Motorola's revenue comes from government agencies, while roughly 25% comes from schools and private businesses. Motorola has customers in over 100 countries and in every state in the United States.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: